Norway to use three vaccines to stop COVID-19 from early 2021

In the first quarter of 2021, Oslo expects to receive a total of 2.5 million doses, covering 1.25 million people.

Updated - December 04, 2020 05:24 pm IST

Published - December 04, 2020 05:18 pm IST - OSLO:

A dose of COVID-19 vaccine of BioNTech and Pfizer is pictured in this undated photo in Mainz, Germany as Britain became the first western country to approve a COVID-19 vaccine. Photo: Handout via Reuters

A dose of COVID-19 vaccine of BioNTech and Pfizer is pictured in this undated photo in Mainz, Germany as Britain became the first western country to approve a COVID-19 vaccine. Photo: Handout via Reuters

Norway plans to use the three vaccines developed by Moderna, AstraZeneca, Pfizer and BioNTech in its first push to inoculate its population against COVID-19 , the country’s health minister said on Friday.

In the first quarter of 2021, Oslo expects to receive a total of 2.5 million doses, covering 1.25 million people, pending approval of the vaccines from European regulators. Norway’s population is 5.4 million.

Non-EU Norway will get access to some of the vaccines obtained by the European Union thanks to Sweden, an EU member that will buy more than it needs and sell them to Norway, right after New Year.

“By Easter, we could be in a completely different situation than today,” Health Minister Bente Hoeie told a news conference. The timeline in Norway is speedier than earlier announced. In October, Prime Minister Erna Solberg had said she expected vaccinations to start in the first half of next year.

Countries worldwide are trying to vaccinate as quickly as possible, as vaccines supplies become available and decide which population groups should get it first. Britain on Wednesday became the first nation in the Western world to approve a COVID-19 vaccine , the one developed by Pfizer and BioNTech.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.